Arachidonic Acid for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Arachidonic Acid for Health & Longevity

Created on 06/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

An essential omega-6 fat in every cell membrane and the raw material for signals that both drive and resolve inflammation. The body clearly needs it; the case for supplementing is weaker. Muscle benefits in trained people are modest and inconsistent; brain and immune uses stay hypothetical. Long-term safety beyond a normal diet remains genuinely uncertain. (Full Review)

Protocol

Standard Dose
1,000–1,500 mg/day
Most-studied athletic dose, used over 6–8 weeks with structured resistance training
Dosing Schedule
Split with meals
Two 500–750 mg doses across meals improves gastrointestinal tolerance; take with food
Use Pattern
Short-term blocks
Goal-directed use in 6–8 week blocks aligned with a training cycle, not a lifelong regimen
Time to effect
Tissue Incorporation
Days to weeks
Incorporated into membrane phospholipids over days to weeks; turns over slowly
Muscle Effect
6–8 weeks
Any muscle-related effect emerged over the full 6–8 week study period, not acutely
Tissue Composition Shift
Several weeks
Dietary changes take several weeks to alter tissue fatty-acid levels

Benefits

Contraindications
  • Active inflammatory disease (inflammatory bowel disease, rheumatoid arthritis)
  • Bleeding or clotting disorders
  • Recent cardiovascular events (myocardial infarction within 90 days)
  • Active cancer
  • Pregnant or breastfeeding women
    •
Key Interactions
  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, warfarin, apixaban, rivaroxaban)
  • NSAIDs (ibuprofen, naproxen, aspirin) and COX-2 inhibitors (celecoxib)
  • Corticosteroids and leukotriene modifiers (montelukast)
  • Fish oil and omega-3 supplements (EPA/DHA)
  • Supplements with additive antiplatelet or pro-bleeding effects (high-dose fish oil, vitamin E, ginkgo, garlic, curcumin)
  • Anti-inflammatory protocols
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Theoretical promotion of inflammation and platelet aggregation
    •
  • Low: Gastrointestinal discomfort; potential worsening of pre-existing inflammatory or thrombotic conditions
    •
  • Speculative: Tumor promotion signaling; disruption of omega-6/omega-3 balance
    •

Monitoring

Marker Target Why
hs-CRP < 1.0 mg/L Detects systemic inflammation that ARA could theoretically aggravate
Omega-3 Index (RBC EPA+DHA) > 8% of total fatty acids Gauges omega-3 status that balances ARA-derived eicosanoids
RBC Arachidonic Acid Mid-range (~8–13%) Establishes baseline ARA status and whether supplementation is even needed
AA:EPA ratio ~3:1 to 8:1 Captures the omega-6/omega-3 eicosanoid balance directly
Platelet function / CBC Within normal reference limits Screens for bleeding/clotting tendency relevant to thromboxane effects
Lipid panel (LDL-C, HDL-C, triglycerides) LDL-C < 100 mg/dL; triglycerides < 100 mg/dL Provides cardiovascular context given the omega-6 debate

Cadence: Baseline, then re-check inflammatory markers at roughly 6–8 weeks (end of a typical supplementation block), and thereafter only if symptoms or risk factors warrant.

Qualitative Assessment

  • Training performance and recovery: improvements in strength, peak power, or perceived recovery during a resistance-training block
  • Joint and gut comfort: new or worsening joint stiffness, swelling, or gastrointestinal upset
  • General energy and well-being: subjective energy, mood, and absence of unusual bruising or bleeding
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.